Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atherogenics Switches Focus For AGI-1067 To Glycemic Control In Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

Atherogenics will begin looking for a new partner for the former atherosclerosis treatment, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



AtheroGenics AGI-1067 Development In Diabetes Takes Step Forward

Positive diabetes data, coupled with earlier cardiovascular outcomes, could facilitate approval of AGI-1067 in era of cautious FDA, firm says.

AtheroGenics AGI-1067 Development In Diabetes Takes Step Forward

Positive diabetes data, coupled with earlier cardiovascular outcomes, could facilitate approval of AGI-1067 in era of cautious FDA, firm says.

AtheroGenics Plans Second Phase III Diabetes Study For AGI-1067

Interim analysis from ongoing ANDES trials shows Atlanta firm’s type 2 diabetes candidate significantly reduced hemoglobin A1c reduction.

Related Content

Topics

UsernamePublicRestriction

Register

PS066121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel